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Background: Few studies have investigated the impact of urinary incontinence (UI) on health-related quality of life
(HRQOL) among cancer survivors. UI is prevalent in the general population and can be both an indicator of cancer
and a side effect of cancer treatment. UI and cancer diagnoses have been associated with decreases in HRQOL. This
study evaluates the prevalence of UI and the impact on HRQOL among older cancer survivors.
Methods: The prevalence of UI among cancer survivors (breast, prostate, bladder, colorectal, lung, and endometrial/
uterine cancers) and those without cancer was estimated using the SEER-MHOS database. Factors associated with
UI were investigated using logistic regression and the impact of UI on SF-36 scores was determined using linear
regression.
Results: Over 36% of SEER-MHOS beneficiaries without cancer reported UI and higher prevalence was noted among
cancer survivors (37%-54% depending on cancer type). History of bladder, breast, endometrial/uterine, or prostate
cancer was associated with higher prevalence of UI. UI was independently associated with both lower physical
component scores (PCS) (−1.27; 95%CI:-1.34,-1.20) and mental component scores (MCS) (−1.75; 95%CI −1.83, -1.68).
A suggested decreasing trend in the prevalence of UI was associated with a longer time since cancer diagnosis.
Conclusions: UI was highly prevalent, especially in bladder, endometrial/uterine, and prostate cancer survivors.
Improved recognition of UI risk among cancer survivors will help clinicians better anticipate and mediate the effect of
UI on individuals’ HRQOL.Background
Longer life spans will contribute to a large-scale population
age shift in the United States over the next two decades. By
the year 2030, there will be 71 million Americans over the
age of 65 years, equivalent to approximately 20% of the U.
S. population [1]. Increasing age is a known risk factor for
many cancers, with more than 60% of new cancers and
70% of cancer deaths occurring in adults over the age of 65
years [2]. Older age is also associated with comorbid health
problems and negative impacts on health-related quality of
life (HRQOL) [3,4].
In the U.S., the prevalence of urinary incontinence
(UI) or symptoms consistent with UI, is approximately
17% among men and 38% among women 60 years of age* Correspondence: whitea@unc.edu
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reproduction in any medium, provided the orand older [5-7]. UI impacts many facets of an individual’s
life, including work productivity and social, physical,
psychological, and sexual health [8-11].
In addition, urinary symptoms can be caused by certain
cancers (e.g., bladder, prostate, and gynecological cancers)
and their treatments (e.g., prostatectomy or hysterectomy)
[12-18]. Very little data exist on the prevalence of UI and
its impact on HRQOL among cancer survivors, especially
in elderly populations.
The current study’s main objectives are to evaluate the
prevalence of UI among Medicare beneficiaries with and
without cancer; to determine factors associated with UI
including cancer type (prostate, breast, colorectal, endomet-
rial/uterine, bladder or lung), demographic, and comorbid
factors; and to investigate the impact of UI on HRQOL.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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SEER-MHOS data linkage
The SEER-MHOS database links two population-based
sources of data that provide detailed information about
Medicare beneficiaries with cancer over age 65 years
(the Surveillance, Epidemiology and End Results
[SEER] program of cancer registries and the Medicare
Health Outcomes Survey [MHOS]). Details of the SEER-
MHOS data linkage have been published previously [19].
Briefly, the MHOS were designed to measure and track
HRQOL outcomes of care provided by health mainten-
ance organizations to Medicare Advantage Organization
(MAO) enrollees. Every year, 1,000 randomly selected
Medicare beneficiaries from each managed care plan
under contract with the Centers for Medicare & Medicaid
Services (CMS) are administered the MHOS. Participants
are invited to complete both a baseline survey and a
follow-up survey 2years later if they remain in the same
managed care plan. The MHOS database includes self-
reported socioeconomic, demographic, co-morbidity, race/
ethnicity, health status, and functional status variables.
The SEER Program of the National Cancer Institute
collects and publishes cancer incidence and survival data
from population-based cancer registries covering approxi-
mately 28% of the U.S. population [20]. The SEER Program
registries routinely collect data on patient demographics,
primary tumor site, tumor morphology and stage at diagno-
sis, first course of treatment, and follow-up for vital status.
The SEER-MHOS linked data are considered by Health
Insurance Portability and Accountability Act of 1996
requirements as a limited data set, requiring the investiga-
tors to sign a data use agreement before receiving the data.
This exception allows for the release of deidentified
SEER-MHOS data without obtaining authorization from
individual patients (see Federal Register, August 14, 2002,
page 53,235). IRB exemption was obtained from University
of North Carolina at Chapel Hill.
Cohort and participant selection
More detailed UI questions were included on the MHOS
in 2003 and in later years. Thus, the current cross-sectional
analysis includes both baseline and follow-up data for five
SEER-MHOS cohorts: 2001 and 2003, 2002 and 2004, 2003
and 2005, 2004 and 2006, 2005 and 2007. For individuals
with cancer and two completed SEER-MHOS surveys,
the first survey after the most recent cancer diagnosis
was selected for analysis. For individuals in MHOS without
cancer, the first survey with the more detailed UI questions
answered was selected. Individuals were excluded who (1)
completed only one survey and did not answer the UI
question (n=276 for those with cancer diagnosis, n=6,084
for those without a cancer diagnosis) or (2) had multiple
surveys but the UI question was consistently missing
(n=74 for those with cancer diagnosis, n=1,130 for thosewithout cancer diagnosis). Men with breast cancer were
also removed from the analysis (n=8) as there were too few
to produce reliable prevalence estimates. Among women
with gynecological cancer, we included only those with
endometrial and uterine diagnoses as other gynecological
cancer sample sizes were also too small to produces
reliable estimates. Medicare beneficiaries who were classi-
fied as never diagnosed with cancer did not match to
records in SEER and also responded negatively to the
following question on the MHOS questionnaire: ‘Has a
doctor ever told you that you had any cancer (other than
skin cancer)?’ Records were ascertained for 6 different
cancer types including (1) prostate (n=3,258), (2) breast
(n=2,828), (3) colorectal (n=1,739), (4) endometrial and
uterine (n=562), (5) bladder (n=749), and (6) lung (n=662),
and for participants who had never been diagnosed with
cancer (n=319,734).Measures
UI was defined by an affirmative to the following question:
“Many people experience problems with urinary incontin-
ence, the leakage of urine. In the previous six months, have
you accidentally leaked urine? (yes/no)”. Further investiga-
tion of UI symptom bother was addressed in the following
questions: (1)”How much of a problem, if any, was the
urine leakage for you? (big problem/small problem/not a
problem)”; (2)”Have you talked to your current doctor or
other health provider about your urine leakage problem?
(yes/no)”; and (3) “There are many ways to treat urinary
incontinence including bladder training, exercises, medi-
cation and surgery. Have you received these or any
other treatments for your current urine leakage problem?
(yes/no).”
HRQOL scores were assessed by the Short-Form 36
(SF-36, version 1) and the Veterans Rand-12 (VR-12), which
are scored on a T-score metric with higher scores reflecting
better health. The MHOS moved from using the SF-36 to
the VR-12 in 2006, consequently affecting the surveys
from the last two cohorts. SF-36 and VR-12 physical
and mental component scores have been rescored, using
a published algorthim, so scores are equivalent [21].
The T-score metric was normed so that the average in
the U.S. population is 50 with a standard deviation of 10
[22]. Two summary scores of the SF-36, Physical Com-
ponent Summary (PCS) and Mental Component Summary
(MCS), were used in this study.
Key covariates in this analysis included: smoking
status, age at survey, sex, race, marital status, educa-
tion, comorbid conditions, and difficulty with activities
of daily living (which was defined as responding af-
firmatively to one or more of the following: difficulty
getting out of a chair, using a toilet, walking, dressing,
eating, bathing).
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Univariate distributions of demographic and clinical
covariates were determined, including: urinary incontin-
ence, smoking status, age at survey, sex, race, marital
status, education, comorbid conditions, difficulty completing
daily activities and time since cancer diagnosis to time
of survey (categorized as: survey within 2 years after
diagnosis, survey within 2-5 years after diagnosis, and
survey >5years after cancer diagnosis). These time periods
were selected to approximately represent active or early
post treatment, short-term survival, and long-term cancer
survival periods, respectively. A chi-square test was used to
test the difference in the distribution of MHOS covariates
between each cancer group and the non-cancer group. For
HRQOL scores, a t-test was used. A variable for time since
diagnosis was not tested for significance as there was not a
clear referent group for which to compare it. The preva-
lence of individuals’ UI was calculated for each cancer type
and for participants without cancer. The prevalence of UI
was also investigated by whether or not the patient reported
being bothered by their UI symptoms or sought treatment
for UI. For all analyses, only those without missing data for
the listed covariates were included in the models.
Logistic regression models were used to examine factors
associated with UI by calculating Prevalence Odds Ratios
(PORs) and 95% Confidence Intervals (95% CIs). These
factors in the model included all cancer types (bladder,
breast, colorectal, endometrial/uterine, lung, and prostate
relative to no cancer group). Other variables were defined
(index/referent) as follows: age at time of survey (>75, ≤75),
smoking status (yes/no), race (other/non-Hispanic white),
gender (male/female), marital status (other/married),
education (> high school, ≤ high school), high blood
pressure (yes/no), stroke (yes/no), chronic lung disease
(including COPD asthma and emphysema) (yes/no),
gastrointestinal (including Crohn’s disease, ulcerative
colitis, and inflammatory bowel disease) (yes/no), diabetes
(yes/no), difficulty completing one or more activities
(getting out of a chair, using the toilet, walking, bathing,
dressing, eating) (yes/no), joint pain (yes/no), and any
cardiovascular disease (one or more of chronic heart
failure, myocardial infarction, angina or coronary artery
disease, or other heart condition) (yes/no). A second logistic
model was performed among cancer survivors (excluding
non-cancer individuals) and included the covariate “time
since cancer diagnosis.” Cancer survivors with colorectal
cancer were chosen as the referent group in this model
due to a similar prevalence of UI compared to the no
cancer group and sample size considerations.
Linear regression models were used to estimate the
adjusted means on the SF-36 subscales and PCS and
MCS scores, by cancer site and urinary symptom status,
adjusting for relevant covariates listed above for the logistic
regression models.All statistical analysis was completed using SAS 9.2
(Cary, NC).Results
The current analysis utilizes data from SEER-MHOS
cohorts who completed surveys between 2001 and 2007.
Individuals were excluded (n=276 for those with cancer
diagnosis, n=6,084 for those without a cancer diagnosis)
if they completed only one survey and did not answer
the UI question or had multiple surveys where the UI
question was always missing (n=74 for those with cancer
diagnosis, n=1,130 for those without cancer diagnosis).
Men with breast cancer were also removed (n=8). After
exclusions the final sample sizes for each of the 6 dif-
ferent cancer types were (1) prostate (n=3,258), (2) breast
(n=2,828), (3) colorectal (n=1,739), (4) endometrial and
uterine (n=562), (5) bladder (n=749), and (6) lung (n=662),
and for those who had never been diagnosed with cancer
(n=319,734).
The distributions of demographic and clinical covariates
by cancer type are shown in Table 1. Only 46.1% of indi-
viduals without cancer were over 75 years of age at time
of survey compared with the cancer groups, which ranged
from 51.1% (lung) to 64.9% (bladder). In general, the
percentage of the no cancer group suffering from comorbid
health conditions tended to be lower than among cancer
survivors. The mean (SD) MCS and PCS scores in the
no cancer population were 50.7 (10.8) and 39.0 (12.2),
respectively. The mean unadjusted PCS scores for those
diagnosed with cancer, except prostate, were all statistically
significantly lower than the mean PCS for participants
without cancer. The percentage of individuals reporting
difficulty completing activities was significantly higher for
those with bladder, breast, colorectal, endometrial/uterine,
and lung cancer than those without cancer. The prevalence
of UI among cancer patients ranged from 37.0% in lung
cancer patients to 53.9% in endometrial/uterine; compared
to a prevalence of 36.2% in the no cancer population.
Prevalence of UI did not significantly vary by time since
diagnosis for all cancer types (data not shown).
Among participants with and without cancer who re-
ported UI, the magnitude of the UI problem was further
explored (Table 2). 13.1% of non-cancer participants
with UI reported that their UI was a “big problem.” The
cancer type with the highest percentage reporting that
their UI was a “big problem” was endometrial/uterine
cancer patients at 20.1%. Cancer patients were in general
more likely than non-cancer participants to talk to their
physician about urinary leakage, although this was only
statistically significantly different for bladder and prostate
cancer patients. Approximately a quarter of the non-cancer
group who reported having UI received treatment, whereas
37.4% of bladder patients received treatment.
Table 1 Distribution of demographic and clinic characteristics by cancer type1
Bladder Breast Colorectal Endometrial/ Lung Prostate No cancer
Uterine
N=749 N=2,828 N=1,739 N=562 N=662 N=3,258 N=319,734
N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Age
>75 486 (64.9) ** 1,604 (56.7)** 1,140 (65.6)** 352 (62.6)** 338 (51.1)* 1,985 (60.9)** 147,523 (46.1)
Current smoker
Yes 114 (15.5)** 227 (8.1)** 128 (7.5)** 19 (3.4)** 121 (18.6)** 295 (9.2)** 35,612 (11.3)
Race
White 648 (88.6) 2,244 (81.6) 1,576 (79.9) 444 (81.6) 524 (81.5) 2,489 (78.7) 279,313 (85.5)
Non- white 83 (11.4)* 507 (18.4)** 338 (20.1)** 100 (18.4)* 119 (18.5)** 673 (21.3)** 45,395 (14.5)
Gender
Female 225 (30.0) 2,828 (100) 883 (50.8) 562 (100) 343 (51.8) 0 (0) 191,922 (60.0)
Male 524 (70.0)** 0 (0) 856 (49.2)** 0 (0) 319 (48.2)** 3,258 (100) 127,812 (40.0)
Marital status
Not married 275 (38.8)** 1,540 (57.2)** 743 (44.8) 297 (56.0)** 297 (47.2) 755 (24.5)** 132,154 (43.8)
Education
> High school 286 (38.8)** 1,053 (37.7)** 608 (35.6)* 214 (38.6)** 227 (35.1) 1,421 (44.4)** 102,928 (32.8)
High blood pressure
Yes 465 (62.8) 1,797 (64.6)** 1,087 (63.2) 359 (64.5) 388 (59.5) 1,891 (58.7)** 193,321 (61.1)
Stroke
Yes 87 (11.8)* 218 (7.8)* 193 (11.3)** 40 (7.2) 82 (12.6)** 345 (10.7)** 28,737 (9.1)
Cardio vascular disease
Yes 339 (45.6)** 833 (29.7)** 605 (35.2) 169 (30.2) 264 (40.4)** 1,136 (35.1) 107,374 (33.8)
Chronic lung disease
Yes 123 (16.9)* 392 (14.1) 228 (13.4) 59 (10.7)* 290 (44.8)** 446 (13.9) 44,038 (14.0)
Gastro intestinal problems
Yes 40 (5.5) 153 (5.6) 173 (10.4)** 39 (7.1)* 30 (4.7) 130 (4.1)* 15,847 (5.1)
Diabetes
Yes 162 (22.1) 567 (20.4) 394 (23.1)** 122 (22.1) 138 (21.1) 664 (20.6) 64,412 (20.4)
Difficulty
Yes 379 (50.9)** 1,334 (47.5)** 816 (47.6)* 306 (54.8)** 402 (61.4)** 1,415 (43.9) 142,992 (45.0)
Joint pain
Yes 377 (50.9) 1,603 (57.2)** 827 (48.1)** 319 (57.4)* 311 (47.4)* 1,498 (46.2)** 165,509 (52.1)
UI
Yes 280 (37.9) 1,296 (46.5)** 635 (37.1) 299 (53.9)** 241 (37.0) 1,416 (44.1)** 113,995 (36.2)
MCS
Mean (SD) 49.5 (10.9)** 51.1 (10.6) 50.1 (10.7)* 51.5 (10.7)** 46.3 (12.2)** 51.0 (10.6) 50.7 (10.8)
PCS
Mean (SD) 37.0 (11.6)** 37.3 (12.0)** 37.6 (11.8)** 36.4 (12.1)** 31.7 (11.4)** 39.4 (11.9)* 39.0 (12.2)
Time since cancer diagnosis
<2years 213 (28.4) 567 (20.0) 392 (22.5) 66 (11.7) 342 (51.7) 716 (22.0) N/A
2-5years 172 (23.0) 614 (21.7) 403 (23.2) 62 (11.0) 110 (16.6) 811 (24.9) N/A
≥5years 364 (48.6) 1,647 (58.2) 944 (54.3) 434 (77.2) 210 (31.7) 1,731 (53.1) N/A
1Two-tailed p-value for chi-squared test, comparing distribution of covariate of cancer group to no cancer group where applicable, or t-test for HRQoL scores.
* p <0.05.
** p <0.01.
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Table 2 Magnitude of UI problem by cancer among those who reported UI1
Bladder Breast Colorectal Endo/ Uterine Lung Prostate No cancer
N (%) N (%) N (%) N (%) N (%) N (%) N (%)
N=280 N=1,296 N=635 N=299 N=241 N=1,416 N=113,995
Magnitude of UI problem Big 50 (13.3) 240 (14.9) 120 (13.9) 60 (20.1) 47 (14.2) 266 (14.5) 20,675 (13.1)
Small 174 (46.3) 769 (47.9) 380 (44.0) 169 (56.4) 150 (45.3) 839 (45.7) 69,052 (43.9)
Not a problem 152 (40.4) 597 (37.2)** 364 (42.1) 70 (23.5) 134 (40.5) 731 (39.8)* 67,607 (43.0)
Talked to physician about UI Yes 175 (54.3)** 514 (36.9) 257 (34.0) 112 (44.4) 110 (37.7) 878 (56.5)** 47,655 (35.4)
Received treatment for UI Yes 107 (37.4)** 291 (24.9) 135 (21.4) 74 (37.0) 50 (19.2) 477 (34.0)** 27,238 (24.1)
1Two-tailed p-value for chi-squared test, comparing distribution of covariate of cancer group to no cancer group.
* p <0.05.
**p<0.01.
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and non-cancer groups, factors associated with UI were
identified (Table 3). Prevalence Odds Ratios (PORs) and
95% confidence intervals were calculated from logistic
models due to the cross-sectional data structure. Being
diagnosed with prostate cancer (POR=2.43, 95% CI: 2.25,
2.63) was associated with the largest increase in odds
of prevalent UI, as was being diagnosed with bladder
(POR=1.25, 95% CI: 1.06, 1.47) and endometrial/uterine
(POR=1.31, 95% CI: 1.09, 1.58) cancers; whereas being
diagnosed with either colorectal or lung cancer was not
associated with an increase in the odds of UI. OlderTable 3 Logistic regression results for associations with UI co
Variable
Cancer type1 Bladder
Breast
Colorectal
Endometrial/Uterine
Lung
Prostate
Demographics Age (>75years)
Current Smoker
Race (non-white)
Gender (male)
Marital Status (not married)
Education (> high school)
Comorbid conditions High blood pressure
Stroke
Chronic lung disease
Gastrointestinal problems
Diabetes
Joint Pain
Cardiovascular disease
Activities of daily living Difficulty
1Noncancer participants are referent for cancer type.age, being a non-smoker, non-Hispanic white race, fe-
male gender, higher education, difficulty completing
activities, and the presence of stroke, chronic lung disease,
gastrointestinal problems, diabetes, joint pain, and cardio-
vascular disease were also associated with increased odds
of UI. Two of the strongest factors associated with UI
were being female (POR (male)=0.42, 95% CI: 0.41, 0.43)
and having difficulty completing activities (POR=1.95,
95% CI: 1.91, 1.98). When fitting the same model only
among cancer patients, a slight decrease in odds of UI
(Table 4; POR=0.88, 95% CI 0.77, 1.01) was observed
for cancer survivors between 2-5 years from diagnosismpared to older Americans without cancer
POR 95% CI P
1.25 (1.06, 1.47) 0.01
1.10 (1.02, 1.20) 0.02
1.07 (0.95, 1.19) 0.3
1.31 (1.09, 1.58) 0.004
0.96 (0.80, 1.14) 0.6
2.43 (2.25, 2.63) <.0001
1.20 (1.18, 1.22) <.0001
0.87 (0.85, 0.89) <.0001
0.69 (0.67, 0.71) <.0001
0.42 (0.41, 0.43) <.0001
1.01 (0.99, 1.03) 0.2
1.33 (1.31, 1.35) <.0001
1.02 (1.00, 1.03) 0.06
1.34 (1.31, 1.38) <.0001
1.19 (1.16, 1.22) <.0001
1.40 (1.35, 1.45) <.0001
1.15 (1.12, 1.17) <.0001
1.45 (1.42, 1.47) <.0001
1.21 (1.19, 1.23) <.0001
1.95 (1.91, 1.98) <.0001
Table 4 Logistic regression results for associations with UI among cancer cases, controlling for time since diagnosis
Variable POR 95% CI P
Cancer type1 Bladder 1.12 (0.92, 1.37) 0.3
Breast 1.15 (0.99, 1.34) 0.08
Colorectal referent – -
Endometrial/Uterine 1.39 (1.11, 1.74) 0.005
Lung 0.90 (0.73, 1.12) 0.4
Prostate 1.95 (1.66, 2.29) <.0001
Demographics Age (>75years) 1.12 (1.02, 1.24) 0.01
Current Smoker 0.98 (0.84, 1.14) 0.8
Race (non-white) 0.82 (0.73, 0.92) 0.0001
Gender (male) 0.55 (0.47, 0.66) <.0001
Marital Status (not married) 1.03 (0.94, 1.14) 0.5
Education (> high school) 1.22 (1.11, 1.34) <.0001
Comorbid conditions High blood pressure 1.00 (0.91, 1.10) 0.9
Stroke 1.31 (1.13, 1.53) 0.0005
Chronic lung disease 1.10 (0.97, 1.25) 0.1
Gastrointestinal problems 1.38 (1.14, 1.68) 0.001
Diabetes 1.23 (1.09, 1.37) 0.0004
Joint Pain 1.66 (1.36, 1.63) <.0001
Cardiovascular disease 1.49 (1.00, 1.22) 0.05
Time from cancer to survey <2years referent – -
2-5years 0.88 (0.77, 1.01) 0.07
≥5years 0.94 (0.84, 1.05) 0.3
Activities of daily living Difficulty 1.66 (1.50, 1.83) <.0001
1Colorectal cancer patients within 2years of treatment are referent group.
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similar small decrease in odds of UI was seen for can-
cer survivors more than 5 years from their diagnosis
(POR=0.94, 95%CI 0.84, 1.05).
Results from linear regression of variables associated
with MCS and PCS, are presented in Table 5. UI was
significantly associated with a 1.27 point decrease in PCS
score (β=−1.27, 95% CI: -1.34, -1.20) and an almost 2-point
reduction in MCS (β=−1.75, 95% CI: -1.83, -1.68), after
adjusting for cancer type, demographics, and comorbidities;
although these differences may not be clinically relevant.
All of the cancer types had negative associations with
PCS; with lung cancer being associated with the largest
detrimental effect on PCS score (β=−4.25, 95% CI: -4.95,
-3.54) relative to the non-cancer group. Of the cancer
types, only lung cancer had a significant negative impact
on MCS scores with a decrease on average of 2.77 points
(β=−2.77, 95% CI: -3.57, -1.97) relative to non-cancer par-
ticipants. Difficulty completing activities of daily living
resulted in the largest decrease in both PCS (β=−12.95,
95% CI: -13.02, -12.88) and MCS (β=−5.57, 95% CI: -5.65,
-5.49) compared to those who did not report any difficulty
with activities of daily living.Discussion
To our knowledge, this is the first study to assess the
prevalence of UI, identify factors associated with UI, and
determine the HRQOL impact of UI in older Americans
with and without cancer. Among this population of
Medicare beneficiaries age 65 years or older, UI was highly
prevalent with over one-third of non-cancer participants
reporting UI. A higher prevalence of UI was observed for
all cancer types included in this analysis compared to the
non-cancer population, although the cancer population
was relatively older. Bladder, endometrial/uterine, and
prostate cancer diagnoses had the strongest associations
with UI. UI was also associated with decreased PCS and
MCS, after controlling for being diagnosed with cancer,
demographic, and comorbid conditions.
There was a suggestion of a decrease in odds of UI with
increasing time from diagnosis among cancer survivors,
relative to the colorectal cancer group which had a similar
prevalence of UI as the non-cancer Medicare beneficiaries.
This may be due to recovery of urinary control after cancer
treatment [23] or adaptation after cancer treatment.
The symptoms and treatments for pelvic cancers, such
as bladder, endometrial/uterine, and prostate cancer, are
Table 5 Linear regression associations with PCS and MCS compared to older Americans without cancer
Variable PCS MCS
β 95% CI P Β 95% CI P
Urinary Incontinence UI −1.27 (−1.34, -1.20) <.0001 −1.75 (−1.83, -1.68) <.0001
Cancer type1 Bladder −1.12 (−1.79, -0.46) 0.0009 −0.59 (−1.35, 0.16) 0.1
Breast −0.72 (−1.06, -0.38) <.0001 0.52 (0.13, 0.91) 0.009
Colorectal −0.85 (−1.29, -0.41) <0.001 −0.28 (−0.78, 0.22) 0.3
Endo/ Uterine −0.39 (−1.16, 0.37) 0.3 1.62 (0.75, 2.48) 0.003
Lung −4.25 (−4.95, -3.54) <.0001 −2.77 (−3.57, -1.97) <.0001
Prostate −0.16 (−0.48, 0.16) 0.3 0.17 (−0.19, 0.53) 0.4
Demo-graphics Age (>75years) −1.50 (−1.57, -1.43) <.0001 −0.06 (−0.13, 0.02) 0.1
Current Smoker −0.82 (−0.93, -0.72) <.0001 −2.30 (−2.41, -2.18) <.0001
Race (non-white) −1.09 (−1.18, -1.00) <.0001 −2.09 (−2.20, -1.98) <.0001
Gender (male) 0.76 (0.69, 0.83) <.0001 −0.35 (−0.43, -0.27) <.0001
Marital Status (not married) −0.02 (−0.08, 0.06) 0.6 −1.03 (−1.10, -0.95) <.0001
Education (> high school) 1.62 (1.55, 1.69) <.0001 1.92 (1.84, 1.99) <.0001
Comorbid conditions High blood pressure −0.94 (−1.00, -0.87) <.0001 0.02 (−0.06, -0.09) 0.7
Stroke −2.17 (−2.28, -2.05) <.0001 −2.17 (−2.30, -2.04) <.0001
Chronic lung disease −3.52 (−3.62, -3.43) <.0001 −1.55 (−1.65, -1.44) <.0001
Gastro intestinal problems −1.93 (−2.07, -1.78) <.0001 −3.40 (−3.57, -3.24) <.0001
Diabetes −1.53 (−1.61, -1.45) <.0001 −1.04 (−1.13, -0.94) <.0001
Joint pain −3.50 (−3.57, -3.43) <.0001 −0.57 (−0.65, -0.50) <.0001
Cardiovas cular disease −2.57 (−2.64, -2.50) <.0001 −1.03 (−1.11, -0.95) <.0001
Activities of daily living Difficulty −12.95 (−13.02, -12.88) <.0001 −5.57 (−5.65, -5.49) <.0001
1Noncancer participants are referent for cancer type.
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http://www.biomedcentral.com/1471-2407/13/377known to be associated with an increased risk of urinary
incontinence [24,25]. However, the prevalence of UI in
cancer survivors on a population-level has not been
previously examined. Previous research has suggested
that urinary incontinence symptoms may be relatively
common after radical hysterectomy [16-18]. Previously it
has been suggested that women who undergo hysterectomy
for treatment of gynecological cancers may have decreased
quality of life, including decreased sexual function [26,27],
which could explain the higher proportion reporting UI
as a serious concern. In this current study, women with
endometrial/uterine cancer had the highest self-reported
burden of symptoms, labeling their UI a ‘big problem’
The prevalence of UI for individuals without cancer
was comparable to estimates reported previously for
females, although higher than the general population
prevalence estimates previously reported for men [5,6].
However, this is an older population so the prior data with
slightly lower rates are not necessarily applicable to Medi-
care beneficiaries. Our method of using self-reported UI is
possibly a more accurate reflection of the prevalence of UI
symptoms than a clinical measurement as UI is often
underdiagnosed [28]. This is evident given that only 35%
to 57% of the SEER-MHOS participants who self-reportedUI indicated that they had spoken to their doctor about
their UI symptoms.
HRQOL measures were negatively associated with UI,
history of certain cancers, demographics, and comorbid
conditions. UI, regardless of cancer diagnosis and other
covariates in the models, was independently significantly
associated with decreases in both MCS and PCS, especially
larger decreases observed for mental health. This suggests
that UI is an important factor in the lives and health of
Medicare beneficiaries whether or not they have been
diagnosed with cancer.
This study would have benefited from being able to
assess the impact of cancer treatment, particularly sur-
gery, on the prevalence of UI. However, due to large
amounts of missing treatment data in SEER, this was
not possible. Additionally, this analysis was cross-sectional
and therefore is limited in drawing any conclusions
regarding temporality between the cancer diagnosis,
UI, and HRQOL. Although there were a wide range
of variables collected from the MHOS, there were
unmeasured risk factors for UI that we could not
address in this analysis including reproductive history
[29,30] and other urological conditions that could lead
to UI.
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http://www.biomedcentral.com/1471-2407/13/377A strength of this investigation is the large sample size
provide by the linked SEER-MHOS database. The ability
to compare across different cancer types and also between
those with and without cancer is a major advantage of this
analysis. In addition, various demographic and comorbid
conditions that had an impact on HRQOL scores and
prevalence of UI were accounted for in this analysis.Conclusions
With a growing, vulnerable population of cancer survivors
[20], further investigation of health problems survivors are
more likely to face is crucial. In particular, identifying co-
morbid conditions, such as UI, that negatively impact
HRQOL has public health importance, as cancer survivors
already demonstrate decrements in HRQOL scores [25].
Multiple treatment options for persistent UI, particularly
among cancer survivors who had surgery such as prostatec-
tomy and hysterectomy, have been shown to be effective
in lessening symptoms of UI [31-34]. In this study, gastro-
intestinal problems, chronic lung disease and joint pain
were strongly associated with decreased HRQOL scores.
The understanding of UI prevalence and HRQOL impact
of UI among cancer survivors may assist in focusing
survivorship care efforts to improve the long-term health
and HRQOL of this patient population.
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